{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:09:46Z","timestamp":1780448986206,"version":"3.54.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The application of ferric citrate therapy has yielded unexpected benefits in recent years for Chronic kidney disease patients suffering from hyperphosphatemia and iron deficiency -anaemia. Despite this, earlier research on the impact of ferric citrate on NDD-CKD has been contentious.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> The goal of the meta-analysis is to evaluate the evidence regarding the advantages and dangers of ferric citrate for the treatment of hyperphosphatemia and iron deficiency anaemia in NDD-CKD patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Between the start of the study and June 2022, we searched PubMed, Embase, Cochrane, EBSCO, Scopus, Web of Science, Wan Fang Data, CNKI, and VIP databases for randomised controlled trials of iron citrate for hyperphosphatemia and anaemia in patients with NDD-CKD. For binary categorical data, risk ratios (OR) were employed, and for continuous variables, weighted mean differences The effect sizes for both count and measurement data were expressed using 95% confidence intervals<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The meta-analysis includes eight trials with a total of 1281 NDD-CKD patients. The phosphorus-lowering effect of ferric citrate was greater compared to the control group (WMD, \u22120.55, 95% CI, \u22120.81 to \u22120.28; I<jats:sup>2<\/jats:sup> = 86%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Calcium (WMD, 0.092; 95% CI, \u22120.051 to 0.234; <jats:italic>p<\/jats:italic> &amp;gt; 0.05; I<jats:sup>2<\/jats:sup> = 61.9%), PTH (WMD, \u22120.10; 95% CI, \u22120.44 to 0.23; I<jats:sup>2<\/jats:sup> = 75%, <jats:italic>p<\/jats:italic> &amp;gt; 0.05) and iFGF23 (WMD, \u22127.62; 95% CI, \u221221.18 to 5.94; I<jats:sup>2<\/jats:sup> = 20%, <jats:italic>p<\/jats:italic> &amp;gt; 0.05) levels were not statistically different after ferric citrate treatment compared to control treatment. Furthermore, ferric citrate increased iron reserves and haemoglobin. The ferric citrate group had considerably greater levels than the controls. Ferric citrate, on the other hand, may raise the risk of constipation, diarrhoea, and nausea.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This meta-analysis found that ferric citrate had a beneficial effect in the treatment of NDD-CKD, particularly in reducing blood phosphorus levels when compared to a control intervention. It also shown that ferric citrate has a favourable effect on iron intake and anaemia management. In terms of safety, ferric citrate may increase the likelihood of gastrointestinal side effects.<\/jats:p>","DOI":"10.3389\/fphar.2024.1285012","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T05:04:17Z","timestamp":1709787857000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Ferric citrate for the treatment of hyperphosphatemia and iron deficiency anaemia in patients with NDD-CKD: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Xueying","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglan","family":"Lun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwan","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4103\/0300-1652.171616","article-title":"Assessment of some cardiovascular risk factors in predialysis chronic kidney disease patients in Southern Nigeria","volume":"56","author":"Adejumo","year":"2015","journal-title":"Niger. Med. J. J. Niger. Med. Assoc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.spen.2016.12.004","article-title":"Neurological complications of renal disease","volume":"24","author":"Baluarte","year":"2017","journal-title":"Seminars Pediatr. neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"B4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1053\/j.ajkd.2021.09.017","article-title":"Recent and emerging therapies for iron deficiency in anemia of CKD: a review","volume":"79","author":"Bazeley","year":"2022","journal-title":"Am. J. kidney Dis. official J. Natl. Kidney Found."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jnma.2022.05.002","article-title":"Chronic kidney disease emerging trends in children and what to do about it","volume":"114","author":"Beng-Ongey","year":"2022","journal-title":"J. Natl. Med. Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.jrn.2019.01.004","article-title":"Phosphate binders and nonphosphate effects in the gastrointestinal tract","volume":"30","author":"Biruete","year":"2020","journal-title":"J. Ren. Nutr. official J. Counc. Ren. Nutr. Natl. Kidney Found."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1681\/ASN.2018101016","article-title":"A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD","volume":"30","author":"Block","year":"2019","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"B8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5","volume":"65","author":"Block","year":"2015","journal-title":"Am. J. kidney Dis. official J. Natl. Kidney Found."},{"key":"B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/IJNRD.S78040","article-title":"Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide","volume":"9","author":"Cernaro","year":"2016","journal-title":"Int. J. Nephrol. renovascular Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0188712","DOI":"10.1371\/journal.pone.0188712","article-title":"Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease","volume":"12","author":"Chertow","year":"2017","journal-title":"PloS one"},{"key":"B11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bcp.14396","article-title":"Ferric citrate in the management of hyperphosphataemia and iron deficiency anaemia: a meta-analysis in patients with chronic kidney disease","volume":"87","author":"Choi","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1038\/s41598-021-86769-z","article-title":"Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis","volume":"11","author":"Cirillo","year":"2021","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.kisu.2017.07.002","article-title":"Action plan for determining and monitoring the prevalence of chronic kidney disease","volume":"7","author":"Coresh","year":"2017","journal-title":"Kidney Int. Suppl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/sdi.12702","article-title":"Should phosphate management be limited to the KDIGO\/KDOQI guidelines?","volume":"31","author":"Dhillon-Jhattu","year":"2018","journal-title":"Seminars dialysis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00418-018-1711-8","article-title":"Dietary phosphate toxicity: an emerging global health concern","volume":"150","author":"Erem","year":"2018","journal-title":"Histochem. Cell Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.kint.2019.07.026","article-title":"Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease","volume":"96","author":"Francis","year":"2019","journal-title":"Kidney Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s10157-017-1510-x","article-title":"Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency","volume":"22","author":"Iguchi","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1292\/jvms.19-0641","article-title":"Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats","volume":"82","author":"Iida","year":"2020","journal-title":"J. veterinary Med. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am. J. kidney Dis. official J. Natl. Kidney Found."},{"key":"B21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1053\/j.ajkd.2017.04.022","article-title":"Acid load and phosphorus homeostasis in CKD","volume":"70","author":"Khairallah","year":"2017","journal-title":"Am. J. kidney Dis. official J. Natl. Kidney Found."},{"key":"B22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"B23","first-page":"975","article-title":"The effects of iron citrate on serum fibroblast growth factor-23, cardiac function indicators, and the risk of renal function progression in patients with chronic kidney disease","volume":"56","author":"Lin","year":"2021","journal-title":"Chin. Med. J."},{"key":"B24","first-page":"1611","article-title":"Secondary osteoporosis. Disordered bone metabolism in chronic kidney disease","volume":"28","author":"Nakagawa","year":"2018","journal-title":"Clin. calcium"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/ndt\/gfv268","article-title":"Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited","volume":"31","author":"Nakanishi","year":"2016","journal-title":"Nephrol. dialysis, Transplant. official Publ. Eur. Dialysis Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40265-014-0224-6","article-title":"Next-generation phosphate binders: focus on iron-based binders","volume":"74","author":"Nastou","year":"2014","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ckj\/sfu139","article-title":"Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?","volume":"8","author":"Negri","year":"2015","journal-title":"Clin. kidney J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/14740338.2022.2044472","article-title":"An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles","volume":"21","author":"Ogata","year":"2022","journal-title":"Expert Opin. drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1517\/17425255.2016.1110573","article-title":"Iron-based phosphate binders--a new element in management of hyperphosphatemia","volume":"12","author":"Pai","year":"2016","journal-title":"Expert Opin. drug metabolism Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1053\/j.ajkd.2016.05.015","article-title":"Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials","volume":"68","author":"Palmer","year":"2016","journal-title":"Am. J. kidney Dis. official J. Natl. Kidney Found."},{"key":"B31","first-page":"20","article-title":"Clinical management of anemia in patients with CKD","volume":"34","author":"Rivera","year":"2017","journal-title":"G. Ital. Nefrol. organo Uff. della Soc. Ital. Nefrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"17066","DOI":"10.18632\/oncotarget.24899","article-title":"Ferric citrate and ferric EDTA but not ferrous sulfate drive amphiregulin-mediated activation of the MAP kinase ERK in gut epithelial cancer cells","volume":"9","author":"Scheers","year":"2018","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/nep.13245","article-title":"Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study","volume":"24","author":"Schumacher","year":"2019","journal-title":"Nephrol. Carlt. Vic."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1016\/j.xphs.2019.06.021","article-title":"Impact of acid-reducing agents on gastrointestinal physiology and design of biorelevant dissolution tests to reflect these changes","volume":"108","author":"Segregur","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/MNH.0000000000000128","article-title":"Novel iron-based phosphate binders in patients with chronic kidney disease","volume":"24","author":"Shah","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/ndt\/gfv297","article-title":"Serum phosphorus and association with anemia among a large diverse population with and without chronic kidney disease","volume":"31","author":"Tran","year":"2016","journal-title":"Nephrol. dialysis, Transplant. official Publ. Eur. Dialysis Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"B37","first-page":"241","article-title":"Hyperphosphatemia in chronic kidney disease (CKD)","volume":"46","author":"Wang","year":"2015","journal-title":"Sheng li ke xue jin zhan Prog. physiology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2215\/CJN.15291219","article-title":"Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a randomized trial","volume":"15","author":"Womack","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"B39","doi-asserted-by":"publisher","first-page":"107283","DOI":"10.18632\/oncotarget.21990","article-title":"Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e00042","DOI":"10.1002\/prp2.42","article-title":"VS-501: A NOVEL, NON-ABSORBED, CALCIUM- AND ALUMINUM-FREE, HIGHLY EFFECTIVE PHOSPHATE BINDER DERIVED FROM NATURAL PLANT POLYMER","volume":"2","author":"Wu-Wong","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.3892\/etm.2017.5287","article-title":"\u03b1-klotho and anemia in patients with chronic kidney disease patients: a new perspective","volume":"14","author":"Xu","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/2040622315589934","article-title":"Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness","volume":"6","author":"Yagil","year":"2015","journal-title":"Ther. Adv. chronic Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD","volume":"9","author":"Yokoyama","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1285012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T05:04:22Z","timestamp":1709787862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1285012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":43,"alternative-id":["10.3389\/fphar.2024.1285012"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1285012","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"article-number":"1285012"}}